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Dr Thomas Waddell (Toronto, Ontario, Canada). Secretory
phospholipase A2 (sPLA2), as you mentioned, is part of a family
that is involved in generating products of arachidonic acid down-
stream. And although a role in host defense, inflammatory injury,
and atherosclerosis has been understood for many years, a specific
role for cancer has been largely overlooked. So congratulations to
you and your supervisor for a foray into this field.
You have convinced me that knockdown of sPLA2 results in in-
hibition of nuclear factor kappa B signaling and, as a result, prolif-
eration in vitro and in vivo. I have some technical questions and 1
overview question. You show nicely that the S2 short-hairpin RNA
was the best 1 of the 3 that you examined in terms of its effect on
reducing phospholipase A2 (PLA2), but what about off-target ef-
fects? Is it the most specific molecule? Were there actually any ef-
fects on other members of the PLA2 family?
Dr Jessica Yu. We actually have looked at 1 other family
member, group IV cystosolic PLA2, and the level does not
change substantially with sPLA2 inhibition. I have not yet looked
at cytosolic phospholipases A2 in the knockdown. There are 12
groups of PLA2 enzymes, so it would be difficult to investigate
all of them.
DrWaddell.On to the next question. I would like to come back
to the data you presented about Ki67 being positive on the perim-
eter of the tumors growing in vivo. Do you have any speculation as
to why that finding might have been seen?
Dr Yu. That is an interesting question with several possibili-
ties. Cells in the dish are under constant selection with puromy-
cin, and when we inject the tumor cells into mice, they are no
longer in a selected environment. I did batch selection, not clonalThe Journal of Thoracic and Carselection, and was actually surprised to see a difference with that
technique.
So maybe the perimeter is where we see proliferation of cells
that are no longer being selected for. Another possibility is, of
course, interactions with the microenvironment at the perimeter
that stimulate proliferation. Microenvironment interaction would
be another interesting study.
Dr Waddell. I think both are good. A third I would suggest
thinking about is the hypoxic environment at the center of the tu-
mor. In fact, a knockdown of PLA2 may make cells more sensitive
to hypoxia.
Next I have a general overview question about the interaction
betweenmalignancy and inflammation. Given that this is a secreted
molecule, what do you think about the possibility of transactiva-
tion of malignant cells by inflammatory leukocytes recruited to
the tumor and secreting PLA2?
Dr Yu. Paracrine signaling has been documented by other
groups—sPLA2 group IIa activation of lung macrophages, specif-
ically. So that likely plays a role.
DrWaddell. The specific experimental suggestion I have in this
context is to do mixtures experiments with the tumors or even just
of your transduced tumor cells. If you are looking for an autocrine
inhibitory effect, you might see it if you have a small proportion of
the S2 knockdown cells mixed in with wild-type cells.
Dr Yu. Yes, that is a good idea.
Dr Dao Nguyen (Miami, Fla). I noticed you used 2 cell lines.
The A549 K-Ras mutant and the H358 is p53 mutant and K-Ras
wild type. Is it K-Ras wild-type?
Dr Yu. They are both K-Ras.
Dr Nguyen. My second question is, regarding the reduction of
growth in vivo, can it be because the cells just slow down; they
don’t die at all? So what is your next plan? We want to eradicate
tumors. We don’t want them to slow down.
Dr Yu. Our inhibition experiments have demonstrated an apo-
ptotic response with high concentrations of inhibitor. At a lower
concentration of the inhibitor we see a little bit more of the cell cy-
cle arrest phenomenon. In terms of the mechanisms behind the 2
different responses, I am not exactly sure yet how to explain that.
Dr Nguyen. You saw a reduction in cell proliferation. Did you
look into cell cycle analysis to see if they actually arrest or if they
undergo apoptosis or senescence?
Dr Yu.Our inhibitor experiments looked at that and I have seen
apoptosis and cell cycle arrest. With the knockdown specifically, I
haven’t looked at cell cycle arrest or apoptosis. But like you said,
sPLA2 knockdown did slow tumor growth.diovascular Surgery c Volume 144, Number 5 1191
